Palazestrant
Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.Palazestrant inhibits 17b-estradiol (E2), inhibits MCF7 and CAMA-1 cell proliferation, and can be used in breast cancer research.
Product Specifications
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
449.6
Molecular Formula
C28H36FN3O
Notes
Research use only, not for human use.
Receptor
Estrogen/progestogen Receptor
CAS Number
2092925-89-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
24849121 3 x 1.0μg DNA
IL1R1 CRISPRa sgRNA lentivector (set of three targets)(Human)
Ask
View Details 
MBS1065596-01 0.02 mg (E-Coli)
Recombinant Rhodospirillum centenum Glycerol kinase (glpK)
Ask
View Details MBS1065596-02 0.02 mg (Yeast)
Recombinant Rhodospirillum centenum Glycerol kinase (glpK)
Ask
View Details 
MBS1065596-03 0.1 mg (E-Coli)
Recombinant Rhodospirillum centenum Glycerol kinase (glpK)
Ask
View Details MBS1065596-04 0.1 mg (Yeast)
Recombinant Rhodospirillum centenum Glycerol kinase (glpK)
Ask
View Details MBS1065596-05 0.02 mg (Baculovirus)
Recombinant Rhodospirillum centenum Glycerol kinase (glpK)
Ask
View Details